Historique du chiffre d'affaires, des bénéfices et des flux de trésorerie d'après les états financiers officiels.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
Voir les graphiques interactifs et les états complets → Modèle de valorisation (DCF) →
| Compte de résultat | TTM → 2026-06-30 | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 | 2018-06-30 | 2017-06-30 | 2016-06-30 | 2015-06-30 | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 | 2009-06-30 | 2008-06-30 | 2007-06-30 | 2006-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiffre d'affaires total | $1.2B | $1.2B | $1.2B | $1.2B | $1.1B | $1.1B | $931M | $739M | $714M | $643M | $563M | $499M | $452M | $358M | $311M | $315M | $290M | $269M | $264M | $257M | $223M | $203M |
| Bénéfice brut | $798M | $799M | $790M | $770M | $770M | $756M | $633M | $483M | $473M | $432M | $375M | $337M | $307M | $251M | $231M | $236M | $225M | $215M | $208M | $205M | $177M | $157M |
| Marge brute % | 65.7% | 65.8% | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% | 65.4% | 66.3% | 67.2% | 66.5% | 67.5% | 67.9% | 70.3% | 74.4% | 75.0% | 77.6% | 79.8% | 79.0% | 79.5% | 79.1% | 77.4% |
| Résultat opérationnel (EBIT) | $272M | — | $102M | $207M | $299M | $297M | $237M | $157M | $126M | $136M | $122M | $151M | $147M | $160M | $158M | $166M | $163M | $156M | $151M | $144M | $124M | $109M |
| Marge opérationnelle % | 22.4% | — | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% | 21.3% | 17.6% | 21.2% | 21.6% | 30.2% | 32.5% | 44.6% | 51.0% | 52.8% | 56.2% | 58.1% | 57.1% | 56.0% | 55.5% | 53.5% |
| Résultat net | $182M | $182M | $73M | $168M | $285M | $272M | $140M | $229M | $96M | $125M | $77M | $104M | $108M | $111M | $113M | $112M | $112M | $110M | $105M | $104M | $85M | $73M |
| Marge nette % | 15.0% | 15.0% | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% | 31.0% | 13.5% | 19.5% | 13.7% | 20.9% | 23.8% | 31.0% | 36.2% | 35.7% | 38.7% | 40.8% | 39.9% | 40.2% | 38.1% | 36.2% |
| EBITDA | — | — | $217M | $313M | $457M | $414M | $250M | $378M | $212M | $201M | $182M | $193M | $184M | $179M | $173M | $175M | $174M | $165M | $159M | $152M | $137M | $115M |
| Bénéfice par action (EPS) | $1.16 | $1.16 | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $1.45 | $0.62 | $0.82 | $0.52 | $0.70 | $0.72 | $0.75 | $0.76 | $0.76 | $0.76 | $0.73 | $0.69 | $0.66 | $0.54 | $0.46 |
| Actions en circulation (M) | — | — | 160M | 161M | 162M | 164M | 162M | 158M | 156M | 152M | 150M | 149M | 149M | 148M | 148M | 148M | 149M | 149M | 152M | 157M | 158M | 158M |
Source : rapports publics de la société (SEC). Vérifiez sur SEC EDGAR avant de vous fier à tout chiffre.
Bilans, flux de trésorerie, données trimestrielles et ratios complets dans le visualiseur interactif de TECH. /companies/us/TECH
Les informations de ce site sont fournies à des fins éducatives et informatives uniquement ; elles ne constituent pas un conseil en investissement. Aucun objectif de cours ni recommandation n'est publié.
About TickerBase · Data methodology & sources · Privacy · Terms